Bavarian Nordic is a leading industrial biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's clinical pipeline targets cancer and infectious diseases.
With operations in Denmark, Germany, the USA, and Singapore, Bavarian Nordic employs over 400 people.
Bavarian Nordic's patented technology, MVA-BN®, is as been demonstrated in clinical studies, one of the world's safest, multivalent vaccine vectors for the development of vaccines against various infectious diseases such as smallpox, HIV/AIDS, as well as against breast and prostate cancer. Several MVA-BN®-based HIV, cancer and smallpox vaccines are in clinical Phase I and Phase II trials.
Bavarian Nordic has ongoing development contracts with the US government (awarded in June 2007, September 2004 and February 2003) to develop IMVAMUNE® as a safe non-replicating third-generation smallpox vaccine. Bavarian Nordic's advanced clinical development programme has been further expedited by the US government with the FDA's grant of "fast-track" status for IMVAMUNE®, the first-ever smallpox vaccine candidate to be given this designation.